Literature DB >> 26122542

Regional covariance of muscarinic acetylcholine receptors in Alzheimer's disease using (R, R) [(123)I]-QNB SPECT.

Sean J Colloby1, Ian G McKeith2, David J Wyper3, John T O'Brien4, John-Paul Taylor2.   

Abstract

Alzheimer's disease (AD) is characterised by deficits in cholinergic neurotransmission and subsequent receptor changes. We investigated (123)I-iodo-quinuclidinyl-benzilate (QNB) SPECT images using spatial covariance analysis (SCA), to detect an M1/M4 receptor spatial covariance pattern (SCP) that distinguished AD from controls. Furthermore, a corresponding regional cerebral blood flow (rCBF) SCP was also derived. Thirty-nine subjects (15 AD and 24 healthy elderly controls) underwent (123)I-QNB and (99m)Tc-exametazime SPECT. Voxel SCA was simultaneously applied to the set of smoothed/registered scans, generating a series of eigenimages representing common intercorrelated voxels across subjects. Linear regression identified individual M1/M4 and rCBF SCPs that discriminated AD from controls. The M1/M4 SCP showed concomitant decreased uptake in medial temporal, inferior frontal, basal forebrain and cingulate relative to concomitant increased uptake in frontal poles, occipital, pre-post central and precuneus/superior parietal regions (F1,37 = 85.7, p < 0.001). A largely different perfusion SCP was obtained showing concomitant decreased rCBF in medial and superior temporal, precuneus, inferior parietal and cingulate relative to concomitant increased rCBF in cerebellum, pre-post central, putamen, fusiform and brain stem/midbrain regions (F1,37 = 77.5, p < 0.001). The M1/M4 SCP expression correlated with the duration of cognitive symptoms (r = 0.90, p < 0.001), whereas the rCBF SCP expression negatively correlated with MMSE, CAMCOG and CAMCOGmemory (r ≥ |0.63|, p ≤ 0.006). (123)I-QNB SPECT revealed an M1/M4 basocortical covariance pattern, distinct from rCBF, reflecting the duration of disease rather than current clinical symptoms. This approach could be more sensitive than univariate methods in characterising the cholinergic/rCBF changes that underpin the clinical phenotype of AD.

Entities:  

Keywords:  Alzheimer’s disease; Molecular imaging; Muscarinic receptors; SPECT; Spatial covariance; rCBF

Mesh:

Substances:

Year:  2015        PMID: 26122542     DOI: 10.1007/s00415-015-7827-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  55 in total

1.  Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice.

Authors:  Stephan G Anagnostaras; Geoffrey G Murphy; Susan E Hamilton; Scott L Mitchell; Nancy P Rahnama; Neil M Nathanson; Alcino J Silva
Journal:  Nat Neurosci       Date:  2003-01       Impact factor: 24.884

2.  Network modulation in the treatment of Parkinson's disease.

Authors:  Kotaro Asanuma; Chengke Tang; Yilong Ma; Vijay Dhawan; Paul Mattis; Christine Edwards; Michael G Kaplitt; Andrew Feigin; David Eidelberg
Journal:  Brain       Date:  2006-07-14       Impact factor: 13.501

3.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

4.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

Authors:  Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

5.  CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia.

Authors:  M Roth; E Tym; C Q Mountjoy; F A Huppert; H Hendrie; S Verma; R Goddard
Journal:  Br J Psychiatry       Date:  1986-12       Impact factor: 9.319

6.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

7.  Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease.

Authors:  Derek Brown; Jennifer A Chisholm; Jonathan Owens; Sally Pimlott; Jim Patterson; David Wyper
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-11-26       Impact factor: 9.236

Review 8.  The cerebrovascular role of the cholinergic neural system in Alzheimer's disease.

Authors:  Arenda H E A Van Beek; Jurgen A H R Claassen
Journal:  Behav Brain Res       Date:  2010-01-07       Impact factor: 3.332

9.  Neocortical cholinergic neurons in elderly people.

Authors:  P White; C R Hiley; M J Goodhardt; L H Carrasco; J P Keet; I E Williams; D M Bowen
Journal:  Lancet       Date:  1977-03-26       Impact factor: 79.321

10.  Deficits in iodine-labelled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzheimer's disease.

Authors:  D J Wyper; D Brown; J Patterson; J Owens; R Hunter; E Teasdale; J McCulloch
Journal:  Eur J Nucl Med       Date:  1993-05
View more
  4 in total

1.  Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.

Authors:  Elizabeth Scarr; Catriona McLean; Brian Dean
Journal:  J Neural Transm (Vienna)       Date:  2016-09-29       Impact factor: 3.575

2.  Recent advances in cholinergic imaging and cognitive decline-Revisiting the cholinergic hypothesis of dementia.

Authors:  Nicolaas I Bohnen; Michel J Grothe; Nicola J Ray; Martijn L T M Müller; Stefan J Teipel
Journal:  Curr Geriatr Rep       Date:  2018-01-13

3.  New Developments in Cholinergic Imaging in Alzheimer and Lewy Body Disorders.

Authors:  Chesney E Craig; Nicola J Ray; Martijn L T M Müller; Nicolaas I Bohnen
Journal:  Curr Behav Neurosci Rep       Date:  2020-10-09

4.  A spatial covariance 123I-5IA-85380 SPECT study of α4β2 nicotinic receptors in Alzheimer's disease.

Authors:  Sean J Colloby; Robert H Field; David J Wyper; John T O'Brien; John-Paul Taylor
Journal:  Neurobiol Aging       Date:  2016-07-30       Impact factor: 4.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.